AzTrials
AzTrials

Non Dependant 60 to 75 Year-old Men and WomenMetabotypAGENCT06163794

Multidimensional Phenotyping Towards Personalized Preventive Nutritional Support for Elderly People

A study testing Nutritional postprandial test in people with Non Dependant 60 to 75 Year-old Men and Women, run by Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement at 3 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

There is high inter-individual variability in the response to feeding, which is determined by multiple interacting factors such as age, sex, genotype, gut microbiota, eating behaviors, physical activity or even socio-demographic factors. Read more about this study

Who is it for?
Ages 60 to 75 yearsHealthy volunteers can take part
What is being tested?
Nutritional postprandial test
Could I receive a placebo?
No, everyone receives an active treatment
How many people
250 participants
Where
3 sitesFrance
Study dates
14 Feb 2024to Mar 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 60 to 75 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • - Subject with grip strength (assessed with a dynamometer) ≥16kg for women and ≥26 kg for men.
  • 21 ≤ BMI ≤35
  • Participant living in a rural or peri-urban area or city dweller, according to the population density grid of the Territorial Observatory (categories 3, 2 or 1 respectively).
  • Cognitively able to perform tests and answer questionnaires according to the judgment of the recruiting doctor and on the basis of the Mini-Mental State Examination (MMSE)
  • Available to carry out the entire protocol
  • Biological assessment considered by the investigator as compatible with participation in the study,
  • Subject agreeing to give written consent, and registration in the national file of volunteers who lend themselves to research
  • Person subject to a social security system.

Who cannot join

  • - Diabetes treated
  • Sub-acute pathology (flu, gastroenteritis, bacterial infection, etc.) or trauma (fracture, surgical intervention, etc.) in the 30 days preceding inclusion.
  • Hepatocellular insufficiency,
  • Heart failure with decompensation,
  • Renal insufficiency (clearance <30 ml/min)
  • Chronic anti-inflammatory treatment, long-term corticosteroid therapy > 1 month, infiltrations
Show all 15Show fewer
  • Antibiotic treatment within 30 days prior to recruitment
  • Progressive pathology at the time of inclusion (cancer, etc.)
  • Gastrointestinal pathology deemed incompatible with the protocol
  • Eating habits incompatible with the protocol (allergies, test food intolerances/aversions, vegan diets, ketogenic diets, etc.)
  • Unstabilized thyroid diseases
  • Intense physical activity (activity causing shortness of breath and sweating) > 10 hours per week
  • Person who is in a period of exclusion on the National File of Healthy Volunteers
  • Subject presenting a psychiatric pathology or cognitive disorders making them incapable of giving informed consent.
  • Subject under guardianship, curatorship, deprived of freedoms or under the protection of justice

Trial locations and contacts

3 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Sergio Polakof, Ph D contact

+33473624895

sergio.polakof@inrae.fr

Claudine Manach, Ph D contact

+33473624826

claudine.manach@inrae.fr

France3 sites, 3 recruiting
  • Pic / Cic-Inserm 1405

    Clermont-Ferrand, France, 63000

    Gisèle Pickering, Pr, +33473178416, gisele.pickering@uca.fr

    Recruiting
  • Plateforme d'Exploration de la Mobilité (CHU Clermont-Ferrand)

    Clermont-Ferrand, 63009

    Frédéric Costes, PhD MD

    Recruiting
  • Centre de Recherche en Odontologie Clinique, Faculté de Chirurgie Dentaire

    Clermont-Ferrand, 63100

    Noémie Drancourt, PhD MD

    Recruiting

Other trials in France

About this study

Official title: New Participatory Research Strategy and Multidimensional Phenotyping Towards Personalized Preventive Nutritional Support for Elderly People

There is high inter-individual variability in the response to feeding, which is determined by multiple interacting factors such as age, sex, genotype, gut microbiota, eating behaviors, physical activity or even socio-demographic factors. Original studies have recently demonstrated the possibility of predicting the postprandial response to the diet of healthy individuals on the basis of in-depth phenotyping, and of offering them foods adapted to their own metabolic capacities according to their belonging to different groups of individuals defined on the basis of the similarity of their metabolic capacities. Due to different life trajectories, inter-individual variability could be amplified upon entry into the aging period, which could explain at least in part why traditional strategies for managing chronic age-related pathologies are insufficient. The investigators aim is to propose a new strategy to better understand inter-individual variability in the response to food in the elderly based on deep phenotyping.

Read the detailed description

During a first phase of the project, the investigators defined all the parameters that could be measured to realize a deep phenotyping of volunteers to establish "metabotypes" and have a better understanding of the variability in the response to food. These parameters include: kinetics of change in postprandial blood glucose over a period of 4 hours following home consumption of four types of test meals (composite nutritional test); and measurement of several blood parameters either in the post-absorptive state, or in the post-prandial state, either after test meals at home, or after a fat meal in the research facility: triglycerides, insulin, C-Reactive-Protein, metabolites through open metabolomics, albumin, fatty acids, cytokines, different gene expression. Through questionnaires or tests the investigators will also assess:

food habits and preferences (with a special focus on polyphenols), olfactory and taste abilities, physical activity, muscle functionality, body composition, peripheral endothelial function and microvascular stiffness, blood pressure, oral status, cognitive function, stress and depression status, intestinal function, psycho-socio-economic status. Finally, the investigators will constitute a collection of blood, white cell, plasma, serum, saliva, urine and stool samples.

Being tested
Nutritional postprandial test
Keywords
personalized nutrition, deep phenotyping, inter-individual variability, metabotypes, post-prandial response to food, metabolomics, physical activity and food intake behaviors, aging, citizen science
Medical subject headings
Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Nutritional postprandial testOther

    Metabolic responses to several test meals

Study groups in NCT06163794
Study groupRoleWhat they receive
Non dependant 60 to 75 year-old men and womenExperimentalDeep phenotyping, including metabolic response to nutritional tests.
Receives: Other: Nutritional postprandial test

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Characterize the inter-individual variability of the blood glucose postprandial response

    Kinetics of change in postprandial blood glucose over a period of 4 hours following home consumption of four types of test meals by continuously monitoring blood glucose

    Measured: Within the first month of study realization

Secondary outcomes (30)
  1. Questionnaires about food habits and preferences (with a special focus on polyphenols)

    The investigators' objective is to have a good understanding of eating habits: estimation of precise food intake over three days but also long-term eating habits, preferences for sweet foods, salty foods, fatty foods. Participants will also be questioned about their general appetite, their neophobia, their culinary habits. An effort will be made to estimate polyphenol intake through specific questions.

    Measured: Within the three months of study realization

  2. Test to assess taste abilities

    The participants will be offered drinks containing either water (n=2) or salted water (n=8), with various concentrations of salt. The objective is to determine which drinks contain salt or not. The score will vary from 0 (only bad answers) to 8 (only good answers). A score of 8 thus means that the taste abilities are good.

    Measured: Within the first week of study realization

  3. Test to assess olfactory abilities

    Six groups of 4 vials will be presented to the participants. For each group of 4, only one vial has an odor. The first step will be to find the vial that does contain an odor. Then, the participant will have to identify the odor, choosing among 4 proposed odor. The score will increase with the number of vial found and the number of correct odor identification. It will thus vary from 0 to 8. If a participant has a score of 8, it means that he could detect each time in which vial there was an odor, and could each time identify the odor. Thus a score of 8 denotes very good olfactory abilities.

    Measured: Within the first week of study realization

  4. Time to walk 4 meters

    The time to walk 4 m will be measured.

    Measured: Within the first two months of study realization

  5. Time to stand up 5 times from a chair

    The time to stand up 5 times from a chair will be measured.

    Measured: Within the first two months of study realization

  6. Maximum tolerated muscle power

    The maximum tolerated muscle power will be measured on a cycloergometer

    Measured: Within the first two months of study realization

  7. Maximal isometric strength

    The maximal isometric strength of the quadriceps will be measured on an isometric measuring bench.

    Measured: Within the first two months of study realization

  8. Questionnaires about usual physical activity

    The objective is to assess the amount of time usually spent by the participant for physical activity and for sedentary activities, the intensity of activities, through 28 questions. This questionnaire will give a categorical score, with 3 levels of physical activity: 1) Low: no physical activity or only low intensity activities. 2) Moderate: 3 or more days of intense activity lasting at least 20 min per day, or 5 days or more of moderate intensity activity and/or walking for at least 30 minutes per day, or 5 days or more of activity combining walking, moderate or high intensity activities. 3) Intense activity at least 3 days per week or 7 days or more of activity combining walking, moderate or high intensity activities

    Measured: Within the first two months of study realization

  9. Measurement of total body lean mass (kg)

    Lean body mass will be measured by multi frequency electrical bio impedance (Bodystat QuadScan 4000). A weak electric current is delivered to the subject through electrodes, and the voltage is measured in order to calculate impedance (resistance and reactance) of the body. Most body water is stored in muscle. Therefore, if a person is more muscular there is a high chance that the person will also have more body water, which leads to lower impedance. Using the weight of the participant, through calibration curves, the system then calculates total body water, total body fat mass, and total body lean mass.

    Measured: Within the first two months of study realization

  10. Measurement of total body fat mass (kg)

    Fat body mass will be measured by multi frequency electrical bio impedance (Bodystat QuadScan 4000). A weak electric current is delivered to the subject through electrodes, and the voltage is measured in order to calculate impedance (resistance and reactance) of the body. Most body water is stored in muscle. Therefore, if a person is more muscular there is a high chance that the person will also have more body water, which leads to lower impedance. Using the weight of the participant, through calibration curves, the system then calculates total body water, total body fat mass, and total body lean mass.

    Measured: Within the first two months of study realization

  11. Measurement of peripheral endothelial function (RHI, %)

    Peripheral endothelial function of the participants will be assessed by tonometry using the Endo-PAT X system (Itamar Medical Ltd) before and after induction of post-occlusive reactive hyperemia. Endothelium-induced changes in vascular tone are measured at the fingertip using a pair of single-use plethysmographic sensors. The result obtained is the Reactive Hyperemia Index (RHI, %) which corresponds to the ratio between the amplitudes of the PAT® (Peripheral Arterial Tonometry) signal during hyperemia and the basal amplitudes of the occluded side, normalized by the values of the control arm. The values will be considered as normal if inferior to 1.67, and abnormal if higher than 1.67.

    Measured: Within the first week of study realization

  12. Measurement of microvascular stiffness (Augmentation Index)

    Microvascular stiffness (=Augmentation Index) of the participants will be assessed by tonometry using the Endo-PAT X system (Itamar Medical Ltd). Augmentation Index (AI) will be calculated from the shape of the pulse wave recorded in basal conditions. This measurement is a recognized marker of cardiovascular risk. The AI value is inversely proportional to the stiffness of the vessels. The scale of the measurement is the following:

    Values between 20-80: healthy degree of arterial flexibility. Values between 81-100 : increased cardiovascular risk Values over 100: high cardiovascular risk.

    Measured: Within the first week of study realization

  13. Assessment of oral status

    Oral status will be assessed through the Nordic Orofacial Test - Screening (NOT-S), which is a screening and evaluation tool for orofacial motor dysfunctions and disorders. It includes two parts: 1) "Maintenance" part containing 6 sections: sensory function, breathing, habits, chewing and swallowing, drooling, and dry mouth (I-VI); 2) "Examination" part comprising 6 sections: face at rest, nasal breathing, facial expression, function of the masticatory muscles and jaws, oral motor functions, and articulation of speech. The NOT-S total score ranges from 0 (no dysfunction) to 12 (high dysfunction). For each section, from the moment the subject answers "Yes" to one of the questions, the box is checked and results in a score of 1 in the last right column of the questionnaire.

    Measured: Within the first two months of study realization.

  14. Assessment of cognitive function

    The cognitive abilities of the participants will be assessed using the CANTAB®, using a computer under supervision. This method makes it possible to assess 1) episodic memory; 2) verbal recognition memory, that is, immediate and delayed memory for verbal information; 3) Spatial working memory, which requires the retention and manipulation of visuospatial information. 4) The spatial span task (CANTAB spatial spam), which evaluates the maximum amount of information that the subject is capable of recalling after a single presentation.

    Measured: Within the first week of study realization

  15. Assessment of depression status

    Participants' depressive nature will be assessed using the Geriatric Depression Scale (GDS) test. It is a self-questionnaire which contains 15 items, each with a binary Yes-No response. It is a commonly used tool to assess the presence of depressive symptoms in older adults. A score of 0 to 5 is considered normal. A score between 5 and 9 indicates a high likelihood of depression, and a score between 10 and 15 almost always indicates depression.

    Measured: Within the first week of study realization.

  16. Assessment of socio-economic status

    The socio-economic status of participants will be assessed using the EPICES scale (Évaluation de la Précarité et des Inégalités de santé dans les Centres d'Examens de Santé) which was developed in France by the National Institute of Prevention and Education for Health . This scale is used in public health to assess the social precariousness of individuals, which takes into account the multidimensional nature of precariousness. The main interest of the EPICES score consists of understanding populations which, while escaping the traditional administrative indicators of precariousness, present the same health risks. The EPICES score is based on 11 questions which summarize 90% of a subject's precarious situation. The answer to each question is assigned a coefficient, the sum of the 11 answers gives the EPICES score. The score is continuous, it varies from 0 (absence of precariousness) to 100 (maximum of precariousness).

    Measured: Within the three months of study realization

  17. Assessment of self-esteem

    Participants' self-esteem will be assessed using the Rosenberg Self-Esteem Scale. It is a psychometric tool widely used in psychology research, social sciences and clinical settings. It consists of 10 questions to which respondents are asked to indicate their degree of agreement or disagreement using a 4-point Likert scale, ranging from "strongly disagree" to "strongly agree". The questions are designed to assess overall self-perception and personal esteem. The score between 10 and 40 which are interpreted according to specific thresholds.Higher scores indicate higher self-esteem.

    Measured: Within the three months of study realization

  18. Assessment of intestinal function

    To have a better understanding of the characteristics of the participants' intestinal function, they will have to complete an intestinal transit diary. Such a diary is a tool used to record a person's stool habits and characteristics over a period of time. It is often used in the field of gastroenterology and nutrition to assess the functioning of the digestive system. Participants will note every day for 15 days: the frequency of stools, noting each time the time they had a bowel movement, as well as the consistency of stools based on the Bristol visual scale. which categorizes 7 types of stools, ranging from the hardest to the softest. Experts consider types 1 and 2 to be uncharacteristically hard and indicative of constipation, while types 6 and 7 are unusually loose and may indicate diarrhea. Medical professionals generally consider types 3, 4, and 5 to be the most typical. Overall, a qualitative assessment of intestinal function will be made, with no calculated score.

    Measured: Within the first month of study realization

  19. Stool collection

    One sample of stool will be taken and analyzed by metagenomic.

    Measured: Within the first month of study realization

  20. Measurement of plasma insulin levels (micro U / mL)

    These measurements will be made 1) in the post-absorptive state, 2) after the ingestion of 4 standards test meals, 3) after the ingestion of a sweet and fatty meal.

    Measured: Within the first two months of study realization

  21. Measurement of plasma triglycerides levels (mg / dL)

    These measurements will be made 1) in the post-absorptive state, 2) after the ingestion of 4 standards test meals, 3) after the ingestion of a sweet and fatty meal.

    Measured: Within the first two months of study realization

  22. Measurement of plasma C Reactive Protein (mg / L)

    These measurements will be made in the post-absorptive state.

    Measured: Within the first two months of study realization

  23. Measurement of plasma amino acid levels (µMol)

    These measurements will be made 1) in the post-absorptive state 2) after the ingestion of a protein rich test meal.

    Measured: Within the first two months of study realization

  24. Measurement of plasma metabolite through open metabolomics

    These measurements will be made 1) in the post-absorptive state 2) after the ingestion of a sweet and fatty meal.

    Measured: Within the first two months of study realization

  25. Measurement of plasma free fatty acids (mg / L)

    These measurements will be made 1) in the post-absorptive state 2) after the ingestion of a sweet and fatty meal.

    Measured: Within the first two months of study realization

  26. Measurement of plasma cytokines (U / L)

    These measurements will be made 1) in the post-absorptive state 2) after the ingestion of a sweet and fatty meal.

    Measured: Within the first two months of study realization

  27. Measurement of plasma albumin (g / L)

    These measurements will be made in the post-absorptive state

    Measured: Within the first two months of study realization

  28. Measurement of various gene expression in peripheral blood mononuclear cells isolated from blood samples.

    These measurements will be made in the post-absorptive state

    Measured: Within the first two months of study realization

  29. Measurement of plasma oxylipins (nmol / L)

    These measurements will be made 1) in the post-absorptive state 2) after the ingestion of a sweet and fatty meal.

    Measured: Within the first two months of study realization.

  30. Measurement of immune responsiveness (whole blood oxylipin and cytokine responses to immune stimulation).

    These measurements will be made in the post-absorptive state.

    Measured: Within the first two months of study realization.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Dec 2023
  2. Study start14 Feb 2024
  3. Primary completion30 Jun 2026 (estimated)
  4. Study completionMar 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
250 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06163794
Sponsor's protocol ID
INRAE-UNH-2023-1
Acronym
MetabotypAGE
Status last verified
Feb 2026
First submitted
10 Nov 2023
Last updated
27 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Sharing of all IPD that underlie results in a publication

Publications

  • Ordovas JM, Ferguson LR, Tai ES, Mathers JC. Personalised nutrition and health. BMJ. 2018 Jun 13;361:bmj.k2173. doi: 10.1136/bmj.k2173.

    PubMed 29898881
  • Delude CM. Deep phenotyping: The details of disease. Nature. 2015 Nov 5;527(7576):S14-5. doi: 10.1038/527S14a. No abstract available.

    PubMed 26536218
  • de Toro-Martin J, Arsenault BJ, Despres JP, Vohl MC. Precision Nutrition: A Review of Personalized Nutritional Approaches for the Prevention and Management of Metabolic Syndrome. Nutrients. 2017 Aug 22;9(8):913. doi: 10.3390/nu9080913.

    PubMed 28829397
  • Berry SE, Valdes AM, Drew DA, Asnicar F, Mazidi M, Wolf J, Capdevila J, Hadjigeorgiou G, Davies R, Al Khatib H, Bonnett C, Ganesh S, Bakker E, Hart D, Mangino M, Merino J, Linenberg I, Wyatt P, Ordovas JM, Gardner CD, Delahanty LM, Chan AT, Segata N, Franks PW, Spector TD. Human postprandial responses to food and potential for precision nutrition. Nat Med. 2020 Jun;26(6):964-973. doi: 10.1038/s41591-020-0934-0. Epub 2020 Jun 11.

    PubMed 32528151
  • Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, Ben-Yacov O, Lador D, Avnit-Sagi T, Lotan-Pompan M, Suez J, Mahdi JA, Matot E, Malka G, Kosower N, Rein M, Zilberman-Schapira G, Dohnalova L, Pevsner-Fischer M, Bikovsky R, Halpern Z, Elinav E, Segal E. Personalized Nutrition by Prediction of Glycemic Responses. Cell. 2015 Nov 19;163(5):1079-1094. doi: 10.1016/j.cell.2015.11.001.

    PubMed 26590418
  • Hillesheim E, Ryan MF, Gibney E, Roche HM, Brennan L. Optimisation of a metabotype approach to deliver targeted dietary advice. Nutr Metab (Lond). 2020 Sep 29;17:82. doi: 10.1186/s12986-020-00499-z. eCollection 2020.

    PubMed 33005208

Questions about this trial

What is this clinical trial studying?

A study testing Nutritional postprandial test in people with Non Dependant 60 to 75 Year-old Men and Women, run by Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement at 3 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Sergio Polakof, Ph D (+33473624895, sergio.polakof@inrae.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Characterize the inter-individual variability of the blood glucose postprandial response (time frame: Within the first month of study realization). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06163794, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in